Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122875 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 12
- Study locations
NCT01122875: Completed Phase 1 study of Multiple Myeloma, sponsored by Genentech.
NCT01122875 is a Phase 1 study of Multiple Myeloma that has completed, run by Genentech. The registered enrollment target is 14 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01122875, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
Conditions Studied
Interventions
- DRUG MFGR1877S
Study Locations (12)
Michigan
- - Ann Arbor
- - Detroit
Arizona
- - Scottsdale
Georgia
- - Atlanta
Illinois
- - Chicago
Massachusetts
- - Boston
New Jersey
- - Hackensack
New York
- - New York
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT01122875 record still lists
NCT01122875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MFGR1877S is the first listed.
NCT01122875 lists 12 locations in 11 states (Michigan, Arizona, Georgia).
Frequently Asked Questions
What is clinical trial NCT01122875 about?
NCT01122875 is a clinical study titled "A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma". This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
What is the current status of trial NCT01122875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-11. Estimated completion is 2012-05.
What conditions does trial NCT01122875 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01122875?
The interventions under investigation include: MFGR1877S (DRUG).
Who is sponsoring clinical trial NCT01122875?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01122875 being conducted?
This trial has 12 study locations across Arizona, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01122875's enrollment target sits among peer trials
14 411th of 438 higher than 25 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia